OTHER INCOME (NET)

12 Months Ended

Dec. 31, 2017

Other Nonoperating Income (Expense) [Abstract]

Other Income and Other Expense Disclosure [Text Block]

OTHER INCOME (NET)

Other income (net) includes:

	Year Ended December 31,
Dollars in Millions	2017			2016			2015
Interest expense	$	196		$	167		$	184
Investment income	(154		)	(105		)	(101		)
Provision for restructuring	293			109			118
Litigation and other settlements	(487		)	47			159
Equity in net income of affiliates	(75		)	(77		)	(83		)
Divestiture gains	(164		)	(576		)	(196		)
Royalties and licensing income	(1,351		)	(719		)	(383		)
Transition and other service fees	(37		)	(238		)	(122		)
Pension charges	162			91			160
Intangible asset impairment	—			15			13
Equity investment impairment	5			45			—
Written option adjustment	—			—			(123		)
Loss on debt redemption	109			—			180
Other	(16		)	(44		)	7
Other income (net)	$	(1,519	)	$	(1,285	)	$	(187	)

• Litigation and other settlements includes BMS's share of a patent-infringement settlement of $481 million related to Merck's PD-1 antibody Keytruda* in 2017 and $90 million in 2015 for a contractual dispute related to a license.

• Royalties and licensing income includes upfront licensing fees of $470 million from Biogen and Roche in 2017.

• Transition and other service fees were primarily related to the divestiture of the diabetes and investigational HIV medicines businesses.

• Written option adjustment includes the change in fair value of the written option liability attributed to the Reckitt alliance.

• Other includes an unrealized foreign exchange loss of $52 million in 2015 resulting from the remeasurement of the Bolivar-denominated cash and other monetary balances of BMS’s wholly-owned subsidiary in Venezuela as of December 31, 2015.